Adrenergic drugs for urinary incontinence in adults
Evidence SummariesLevel of Evidence = C
Adrenergic agonist drugs may be be more effective than placebo in reducing incontinence episodes and subjective symptoms.
A Cochrane review (abstract , review ) included 22 studies with a total of 1,099 patients (11 were crossover trials). The studied adrenergic drugs included phenylpropanolamine (11 trials), midodrine (2 trials), norepinephrine (3 trials), clenbuterol (3 trials), terbutaline, eskornade and Ro-115-1240 (1 trial each). The limited evidence suggested that an adrenergic agonist drug is better than placebo in reducing the number of pad changes and incontinence episodes, as well as improving subjective symptoms. In two small trials, the drugs also appeared to be better than pelvic floor muscle training, possibly reflecting relative acceptability of the treatments to women but perhaps due to differential withdrawal of women from the trial groups. There was not enough evidence to evaluate the use of higher compared to lower doses of adrenergic agonists nor the relative merits of an adrenergic agonist drug compared with oestrogen, whether used alone or in combination. Over a quarter of women reported adverse effects. There were similar numbers of adverse effects with adrenergics, placebo or alternative drug treatment. However, when these were due to recognised adrenergic stimulation (insomnia, restlessness and vasomotor stimulation) they were only severe enough to stop treatment in 4% of women.
Comment: The quality of evidence is downgraded by study quality (inadequate or unclear allocation concealment) and by indirectness (problems of generalizability due to studied interventions).
1. Alhasso A, Glazener CM, Pickard R, N'dow J. Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev 2005 Jul 20;(3):CD001842. [PMID:16034867]
Copyright © 2017 Duodecim Medical Publications Limited.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.